FindTrial
Sign In

The efficacy of paritaprevir and ombitasvir with a booster dose of ritonavir in genotype 1 HCV patients with hemodialysis

The efficacy of paritaprevir and ombitasvir with a booster dose of ritonavir in genotype 1 HCV patients with hemodialysis - Viek-tory HD study

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022563
Enrollment
30
Registered
2016-06-01
Start date
2016-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients chronically infected with genotype 1 hepatitis C virus

Interventions

administration of paritaprevir and ombitasvir with a booster of ritonavir for 12 weeks

Sponsors

Mitsui Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patients with written consent of this study 2) patients infected with HCV genotype 1 with chronic hepatitis or with compensated cirrhosis 3) patients without contraindications to paritaprevir, ombitasvir, or ritonavir.

Exclusion criteria

Exclusion criteria: 1) patients who are allergic to paritaprevir, ombitasvir, or ritonavir. 2) patients with decompensated cirrhosis (Child-Pugh Class B or C) 3) pregnant women and women suspected of being pregnant 4) patients ineligible for some other reasons

Design outcomes

Primary

MeasureTime frame
antiviral effect (24 weeks after end of administration)—

Secondary

MeasureTime frame
1) antiviral effect (4 weeks after end of administration) 2) the improvement of liver function at the end of treatment 3) adverse events—

Countries

Japan

Contacts

Public ContactTakamasa Ohki

Mitsui Memorial Hospital Department of Gastroenterology

anb72547@nifty.com03-3862-9111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026